Company Update

Securities and Exchange Commission on March 23, 2017, the PRH Group concluded its best efforts activity to arrange for a financing of $20,000,000 (the “Financing”), which amounts were provided in a number of tranches, between the first tranche on April 4, 2017 and the final tranche on December 20, 2019 (the “Final Tranche”). As described in the Term Sheet, the Financing was in the form of a secured convertible loan (the “Loan”) from various investors (collectively, the “Investors”) that is evidenced by convertible promissory notes (individually, a “PRH Note” and collectively, the “PRH Notes”) and secured by a first priority security interest on the Company’s intellectual property (the “IP”). Pursuant to the Term Sheet, the PRH Notes will convert into shares of Series D Preferred Stock of the Company on or before June 20, 2021, which is the 18-month anniversary of the funding of the Final Tranche of the Financing, subject to certain exceptions. As of the date hereof, the Series D Preferred Stock had not yet been designated by the Company’s board of directors. Upon conversion of the Loan, the Investors will release their first lien on the IP. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 26, 2019 PROVECTUS BIOPHARMACEUTICALS, INC. By: /s/ Heather Raines Heather Raines Chief Financial Officer (Principal Financial Officer)